Cardiovascular Disease
Evidence-based use of levosimendan is reviewed in different clinical settings
Published in Heart Disease Weekly, October 22nd, 2006
According to that review, "Levosimendan is a new calcium sensitizer and KATP channel opener. Compared with other inodilators, it improves myocardial contractility without increasing oxygen requirements and induces peripheral and coronary vasodilation with a potential anti-stunning, anti-ischaemic effect."
L. Deluca and colleagues at European Hospital in Rome wrote, "The documentation regarding levosimendan is one of the largest ever on the safety and efficacy of a new pharmacological agent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
Source: Heart Disease Weekly (2006-10-22)
More Articles from Heart Disease Weekly
- Cardiology
Arrhythmogenic RV cardiomyopathy shows ultrastructural evidence of intercalated disc remodeling - Cardiology
Human ventricular fibrillation shows evidence of multiple mechanisms - Cardiomyocytes
Aspects of cardiomyocyte hypertrophy are antagonized by nuclear targeting of Akt - Marfan Syndrome
Optimal management of Marfan syndrome requires careful monitoring of entire aorta - Statins
Reduced atrial fibrillation prevalence is associated with lipid-lowering drug use - Anaphylactic Shock
Anaphylactic shock depends on PI3K and eNOS-derived NO - More from this issue of Heart Disease Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
